Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common Stock
Rhea-AI Summary
Spyre Therapeutics (Nasdaq: SYRE) priced an upsized underwritten offering of 6,500,000 common shares at $62.00 per share, raising approximately $403.0 million gross before fees.
The company granted underwriters a 30-day option to purchase up to an additional ~$60.5 million of shares; closing is expected on or about April 16, 2026, subject to customary conditions.
Positive
- Gross proceeds of approximately $403.0 million
- Underwriter option enables up to ~$60.5 million additional capital
Negative
- Issuance of 6,500,000 new shares may dilute existing shareholders
- Closing is subject to customary conditions, not yet finalized
News Market Reaction – SYRE
In the Apr 15 session, SYRE gained 7.78%, reflecting a notable positive market reaction. Argus tracked a peak move of +5.2% during that session. Our momentum scanner triggered 16 alerts that day, indicating notable trading interest and price volatility. Trading volume was very high at 3.0x the daily average, suggesting strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Offering Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 13 | Equity offering proposed | Negative | +1.2% | Announced proposed $300.0M common stock offering with 30-day underwriter option. |
| Oct 15 | Equity offering closed | Negative | +0.2% | Closed $316.2M offering of 17,094,594 shares including full underwriter option. |
| Oct 13 | Equity offering priced | Negative | +11.0% | Priced $275.0M offering of 14,864,865 shares at $18.50 per share. |
| Oct 13 | Offering proposed | Negative | +11.0% | Commenced offering of common stock and pre-funded warrants with 30-day option. |
| Nov 18 | Equity offering priced | Negative | -6.2% | Priced $200.0M offering of 7,275,000 shares at $27.50 per share. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Equity offerings for SYRE have often seen counterintuitive price strength: 4 of 5 past offering headlines coincided with flat-to-positive moves despite dilutive implications.
Over the past 18 months, Spyre has repeatedly tapped the capital markets via S-3 shelves and follow-on offerings. Prior deals included a $200.0M offering in Nov 2024 and a $275.0M pricing plus $316.2M closing in Oct 2025. An additional proposed $300.0M offering was announced on Apr 13, 2026. Today’s upsized $403.0M deal continues this pattern of raising sizeable equity after positive clinical updates, with past offerings often met by resilient or even positive share reactions.
Key Terms
underwritten public offering financial
common stock financial
prospectus supplement regulatory
registration statement regulatory
form s-3 regulatory
book-running managers financial
base prospectus regulatory
securities and exchange commission regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., April 14, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory Bowel Disease (“IBD”) and other immune-mediated diseases, today announced the pricing of its previously announced underwritten public offering of 6,500,000 shares of its common stock at a price to the public of
The offering is expected to close on or about April 16, 2026, subject to satisfaction of customary closing conditions. Jefferies LLC, Goldman Sachs & Co. LLC, Evercore ISI, and Guggenheim Securities, LLC are acting as the joint book-running managers for the offering. LifeSci Capital LLC is acting as passive bookrunner for the offering.
A registration statement on Form S-3 (File No. 333-293600) relating to these securities has been filed with the Securities and Exchange Commission (the “SEC”) and became effective on February 27, 2026. This offering is being made solely by means of a prospectus supplement and accompanying prospectus. A preliminary prospectus supplement and accompanying base prospectus relating to and describing the terms of the offering has been filed with the SEC and is available on the SEC's website located at http://www.sec.gov. When available, copies of the final prospectus supplement and the accompanying prospectus related to the offering may be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388 or by email at Prospectus_Department@Jefferies.com; Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at (866) 471-2526 or by email at prospectus-ny@ny.email.gs.com; Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th floor, New York, NY 10055, by telephone at (888) 474-0200 or by email at ecm.prospectus@evercore.com; Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, New York, NY 10017, by telephone at (212) 518-9544 or by email at GSEquityProspectusDelivery@guggenheimpartners.com; or LifeSci Capital LLC at 1700 Broadway, 40th Floor, New York, New York 10019, or by email at legalnotices@lifescicapital.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Spyre Therapeutics
Spyre Therapeutics is a clinical-stage biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) and other immune-mediated disease products by combining best-in-class antibody engineering, dose optimization, and rational therapeutic combinations. Spyre’s pipeline includes investigational extended half-life antibodies targeting a4p7, TL1A, and IL-23.
Safe Harbor / Forward-Looking Statements
This press release contains “forward-looking” statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historical fact are forward-looking statements. These forward-looking statements include statements regarding Spyre’s expectations regarding the consummation of the offering and the satisfaction of customary closing conditions related to the offering. The words “believe,” “may,” “will,” “potentially,” “estimate,” “continue,” “anticipate,” “predict,” “target,” “intend,” “could,” “would,” “should,” “project,” “plan,” “expect,” the negatives of these terms, and similar expressions that convey uncertainty of future events or outcomes are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.
These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, market conditions and satisfaction of customary closing conditions related to the offering, uncertainties and risks arising from regulatory feedback, including potential disagreement by regulatory authorities with the Company’s clinical trial design, interpretation of data and the Company’s ongoing or planned clinical trials for its product candidates; the potential for final clinical data not being delivered within expected time frames or final data not being consistent with or different than the previously disclosed data reported for the Company’s programs; the expected or potential impact of macroeconomic conditions, including inflationary pressures, rising interest rates, general economic slowdown or a recession, changes in tariff/trade and monetary policy, volatile market conditions, financial institution instability, as well as geopolitical instability, including the ongoing military conflicts between the United States and Iran, Ukraine and Russia, conflicts in the Middle East, and geopolitical tensions between the United States and other countries, including China, on the Company’s operations; the implementation of changes in law, tariffs, sanctions, export or import controls, and other government measures that could impact the Company’s business operations, including restricting international trade by the United States, China or other countries and the BIOSECURE Act or similar act if passed into law; and those risks described in the Company’s most recent Annual Report on Form 10-K, its subsequent Quarterly Reports on Form 10-Q, as well as in other filings and reports that the Company makes from time to time with the SEC. Moreover, the Company operates in a very competitive and rapidly changing environment, and new risks emerge from time to time. It is not possible for the Company’s management to predict all risks, nor can the Company assess the impact of all factors on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements it may make. In light of these risks, uncertainties, and assumptions, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.
You should not rely upon forward-looking statements as predictions of future events. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. The Company undertakes no obligation to update publicly any forward-looking statement for any reason after the date of this press release to conform these statements to actual results, to reflect changes in the Company's expectations, or otherwise, except as required by law.
For Investors:
Eric McIntyre
VP of Finance and Investor Relations
Spyre Therapeutics
Eric.mcintyre@spyre.com
For Media:
Josie Butler, 1AB
josie@1abmedia.com
